Combined modality therapy for intracranial tumors.
Three types of tumor (supratentorial astrocytoma, medulloblastoma, and craniopharyngioma), each requiring a fundamentally different therapeutic approach, will be used to illustrate the principles and practice of combined treatment in this field. The role of radiotherapy and ways of enhancing the effect of irradiation will be considered. Attention will be given to adjuvant chemotherapy and to multiple drug regimes. Reference will be made to an early effort at immunotherapy following the initial reduction of tumor cell load by surgery and irradiation.
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001254:Astrocytoma / Q000532:radiotherapy / Q000628:therapy*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002330:Carmustine / Q000627:therapeutic use; D002648:Child; D003397:Craniopharyngioma / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D005909:Glioblastoma / Q000532:radiotherapy; D005910:Glioma / Q000532:radiotherapy; D006801:Humans; D006931:Hyperbaric Oxygenation; D007036:Hypothermia, Induced; D007167:Immunotherapy; D008527:Medulloblastoma / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009502:Neutrons; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D011838:Radiation-Sensitizing Agents; D002330:Carmustine